Malaria Prevention Goes Digital for Modern Travelers

WASHINGTON – April 15, 2026 – U.S. travelers preparing for trips to malaria-endemic regions now have a new, streamlined option for obtaining a key preventive medication. In a move that merges modern telehealth with global travel health, 60 Degrees Pharmaceuticals announced its once-weekly malaria pill, ARAKODA® (tafenoquine), is now available through the online travel health platform Runway Health.

The partnership allows travelers to bypass traditional clinic visits by connecting with a licensed healthcare professional online. Following a consultation to determine if the prescription is appropriate, the medication can be delivered directly to their home, simplifying a crucial step in pre-departure planning. This development signals a significant shift towards digital convenience in a field long dominated by in-person appointments.

A New Prescription for Travel Health Convenience

For millions of Americans traveling abroad each year, preparing for health risks can be a cumbersome process. Obtaining prescriptions for preventative medications often requires scheduling appointments with primary care physicians or specialized, and often costly, travel clinics. Runway Health, a telehealth company focused on travel medicine, aims to dismantle these barriers.

The platform offers virtual consultations with board-certified physicians licensed in all 50 states, allowing travelers to receive medical advice and prescriptions from the convenience of their homes. “We are focused on making travel health simple and accessible,” said Josh Rome, founder and Chief Executive Officer of Runway Health, in a statement.

By adding ARAKODA to its offerings, Runway Health provides travelers with another option for malaria prevention, one that stands out for its dosing schedule. “Availability of once-weekly ARAKODA online finally makes travel-related malaria prevention more convenient and accessible,” noted Kristen Landon, chief commercial officer of 60 Degrees Pharma. She added that the partnership "streamlines a critical part of travel to malaria-endemic regions.”

This model directly addresses what market observers call a notoriously fragmented and often antiquated system. For travelers with tight schedules or those living far from specialized clinics, the ability to manage travel health needs online represents a significant improvement in access to care.

Navigating the Crowded Market of Malaria Prevention

ARAKODA, which received FDA approval in 2018, enters a competitive market for malaria prophylaxis. Its primary advantage is its dosing regimen: after an initial three-day loading phase, the medication is taken just once a week during travel and once in the week following the trip. This stands in stark contrast to popular daily alternatives like Malarone (atovaquone-proguanil) and doxycycline.

Proponents argue that a weekly schedule can significantly improve adherence, a critical factor in ensuring the medication's effectiveness. Failure to take daily pills is a common reason for prophylaxis failure among travelers. Furthermore, ARAKODA is a broad-spectrum antimalarial, effective against the two most common malaria parasites, Plasmodium falciparum and Plasmodium vivax, making it suitable for nearly all malaria-endemic areas worldwide.

However, the convenience of ARAKODA comes with important medical considerations. Before a prescription can be written, patients must undergo a blood test to check for Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with this genetic condition are at risk of developing hemolytic anemia, a serious condition where red blood cells are destroyed faster than they can be made. The drug is also contraindicated for patients with a history of psychotic disorders.

This pre-screening requirement is a crucial safety step that prescribers on the Runway Health platform will need to manage. Other common side effects can include headache, dizziness, nausea, and back pain. These factors place ARAKODA in a unique position against its competitors—while its weekly dosing is a major draw, it requires more initial screening than daily options like the widely used generic atovaquone-proguanil, which is often cheaper but requires strict daily use.

Telehealth's Expanding Role in Global Public Health

The collaboration between 60 Degrees Pharma and Runway Health is emblematic of a larger trend: the integration of telehealth into preventative medicine and global public health. As digital health platforms mature, they are increasingly seen as a game-changing solution for making essential care more accessible.

Malaria remains a significant threat, with the CDC diagnosing approximately 2,000 cases in the U.S. annually, almost all in returned travelers. By simplifying access to an effective prophylactic, this new online channel has the potential to increase the number of travelers who are properly protected, thereby reducing the incidence of travel-acquired malaria. The convenience factor is particularly appealing to younger travelers and busy professionals who are accustomed to managing their lives through digital services.

This shift moves a critical public health tool out of the exclusive domain of physical clinics and into the direct-to-consumer digital space. While telehealth platforms must ensure rigorous adherence to medical safety protocols, such as verifying G6PD test results for ARAKODA, their ability to reach a broader audience could have a net positive impact on traveler health and safety on a global scale.

A Strategic Play for Market Share

For 60 Degrees Pharmaceuticals, this partnership is more than just a new distribution channel; it is a key strategic move to bolster ARAKODA's position in the market. Since its commercial launch in 2019, ARAKODA has faced competition from established drugs, particularly the less expensive generic versions of daily pills.

By partnering with a direct-to-consumer platform like Runway Health, the company can market ARAKODA's primary benefit—convenience—directly to travelers. This strategy allows it to tap into a segment of the market that prioritizes ease of use and may be willing to navigate the G6PD testing requirement for the benefit of a weekly pill. It aligns with the company's broader mission to develop and commercialize medicines for vector-borne diseases.

This digital-first approach represents a modern commercialization strategy in the pharmaceutical industry, leveraging technology to overcome brand recognition hurdles and compete effectively against entrenched alternatives. As travelers increasingly turn to online solutions for every aspect of their journey, from booking flights to planning itineraries, integrating healthcare into that digital ecosystem is a logical and potentially lucrative next step for pharmaceutical companies. The success of this initiative could pave the way for more preventative health services to become readily available at the click of a button.